Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Predictive Oncology Inc. (NASDAQ:POAI) announced that it has appointed Pamela Bush as its chief business officer to lead all business development, partnering and growth strategies for the company.  As a key member of the executive team, the company said Bush will spearhead its strategic, operational and financial planning initiatives for both existing customers and emerging new markets.

Predictive Oncology appoints business development veteran Pamela Bush as chief business officer

EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.

Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer

Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed Dr Robert F. Murphy, a pioneer in the field of machine learning and analytics for biological data, to its scientific advisory board.

Predictive Oncology adds Dr Robert F. Murphy to its scientific advisory board

EAGAN, Minn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Robert F. Murphy, Ph.D., to the company's Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy.

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology

AudioEye Inc

Duos Technologies Group

Ideanomics Inc

Innodata

Lantronix

Rekor Systems Inc

There is no denying that Artificial Intelligence (AI) will have a monumental impact on our lives in the upcoming decades. AI has the potential to completely revolutionize how we live and work, allowing us to make life easier and more rewarding for people all over the world.

7 Artificial Intelligence Stocks Under $10 for Your 2023 Watch List

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Chan Zuckerberg Initiative executive Marc Malandro to its Scientific Advisory Board. The Eagan, Minnesota-based company called Malandro “a highly regarded scientific leader with significant experience in business, law and philanthropy.

Predictive Oncology adds Chan Zuckerberg Initiative's Marc Malandro to its scientific advisory board

EAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Marc Malandro, Ph.D., to the company's Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy.

Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Matthew J Hawryluk to its board of directors in support of the company's strategic initiatives and commercialization efforts. With a PhD in cell biology and biochemistry from the University of Pittsburgh School of Medicine, an MBA from Carnegie Mellon University's Tepper School of Business and a BSc from the University of Notre Dame, Dr Hawryluk currently serves as the executive vice president and chief business officer of Gristone bio Inc, Predictive Oncology noted.

Predictive Oncology adds leading biopharma executive Dr Matthew J Hawryluk to its board

EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (Nasdaq: GRTS).

Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D.

Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2022 Earnings Conference Call November 11, 2022 12:00 PM ET Company Participants Theresa Ferguson - Investor Relations Raymond Vennare - Chairman and Chief Executive Officer Pamela Bush - Senior Vice President of Strategic Sales and Business Development Bob Myers - Chief Financial Officer and Site Leader, Skyline Medical Conference Call Participants Michael Broadbent - Bedrock Group Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Predictive Oncology Third Quarter 2022 Earnings Conference Call.

Predictive Oncology Inc. (POAI) Q3 2022 Earnings Call Transcript

Predictive Oncology Inc. (NASDAQ:POAI) has reported revenue growth and an increased gross profit margin in its third quarter as the company continues to gain traction with potential partners with its breakthrough solution at a pivotal time in drug discovery. The company said during the quarter it leveraged its novel artificial intelligence-powered platform paired with the largest privately held biobank of over 150,000 tumor samples to help drug developers make higher confidence predictions of which molecules will and won't be successful, and ultimately leading to greater chances of commercial success.

Predictive Oncology reports 45% revenue jump, increased gross profit margin in 3Q

EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include:

Predictive Oncology Reports Third Quarter Financial Results

Predictive Oncology Inc. (NASDAQ:POAI) is beefing up its board with the appointment of David Smith, a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. In a statement, the Minnesota-based biotech company cited Smith's “extensive transactional experience, venture financings and regulatory matters” for life sciences companies and investors.

Predictive Oncology strengthens board of directors with life sciences and corporate attorney David Smith

Leading authority on the therapeutic use of human tissues and cells Leading authority on the therapeutic use of human tissues and cells

David S. Smith appointed to the Board of Directors of Predictive Oncology

Predictive Oncology Inc has announced the appointment of Raymond Vennare as the company's new CEO and board chairman, effective November 1, 2022.  The company said Vennare, an active member of the Predictive Oncology board of directors since September 2021, will continue to work closely with senior management to expand its portfolio of proprietary solutions to advance the pipeline of drug development in oncology, ranging from early discovery through clinical trials.

Predictive Oncology appoints biotech veteran Raymond Vennare as its new CEO and chairman

EAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1.

Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth

Predictive Oncology Inc. (NASDAQ:POAI) said it has further strengthened its offerings for pharmaceutical and biotech customers through several key developments. The company said the first was its Good Manufacturing Practices (GMP) lab, which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug (IND) qualification, including Phase 1 clinical trials.

Predictive Oncology strengthens pharmaceutical and biotech offering; announces retirement of CEO and chairman J Melville Engle

EAGAN, Minn., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced several key developments to further strengthen the company's offerings for pharmaceutical and biotech customers.

Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development

Predictive Oncology Inc. (NASDAQ:POAI) has announced that J. Melville (Mel) Engle will retire as its chief executive officer, chairman and a member of the company's board of directors.

Predictive Oncology announces retirement of its chief executive officer and chairman, J. Melville Engle

EAGAN, Minn., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that J. Melville (“Mel”) Engle will retire as Chief Executive Officer and as Chairman and a member of the company's Board of Directors. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through October 31, 2022. Pursuant to policies regarding leadership succession, the governance committee of POAI's Board of Directors is working with a succession plan to replace Mr. Engle as Chief Executive Officer.

Predictive Oncology Announces CEO Retirement

Predictive Oncology Inc. (NASDAQ:POAI) said it ended the second quarter of 2022 with a strong balance sheet, a solid cash position, commensurate equity, and no debt. The Minnesota-based company recognized net sales revenue of $400,000 for the three months ended June 30, 2022, an increase of 6% from the year-ago period, mainly due to a $100,000 sales contribution from its zPREDICTA subsidiary which is pioneering tumor-specific 3D cell culture services for anti-cancer drug testing.

Predictive Oncology ends 2Q 2022 with strong balance sheet and solid cash position

EAGAN, Minn., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt. Highlights from the quarter include:

Predictive Oncology Reports Second Quarter 2022 Financial Results

NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Predictive Oncology. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring J.

Traders News Source Senior Editor Mark Roberts Interviews J. Melville Engle, CEO and Chairman of the Board, Predictive Oncology

Predictive Oncology Inc. (NASDAQ:POAI) announced it has appointed Julia Kirshner to the newly-created role of Chief Scientific Officer (CSO). Kirshner, who up until now served as senior vice president at Predictive Oncology and president of its zPREDICTA division, will assume the role on August 1.

Predictive Oncology appoints Julia Kirshner as its new Chief Scientific Officer

EAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner, Ph.D., as Chief Scientific Officer. Dr. Kirshner currently serves as Senior Vice President at Predictive Oncology and President of POAI's zPREDICTA division and will be elevated to the post beginning August 1, 2022.

Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm

News for Predictive Oncology Inc Stock (POAI)